Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Expands By 16.4%

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 12,800 shares, a growth of 16.4% from the November 30th total of 11,000 shares. Based on an average daily volume of 27,000 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the shares of the company are sold short.

Insider Transactions at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The shares were acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the purchase, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 28.79 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Marc Duey purchased 30,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the transaction, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This trade represents a 14.28 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 42,290 shares of company stock worth $165,096 in the last ninety days. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises about 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Stock Performance

Shares of NASDAQ:APRE opened at $3.37 on Monday. The firm has a 50 day moving average of $3.43 and a 200-day moving average of $3.49. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The stock has a market capitalization of $18.32 million, a PE ratio of -1.20 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. On average, research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Tuesday, December 17th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.